Clinical Trials
6 trialsNCT07134088 2026-05-15
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2 Active not recruiting
NCT04521231 2026-05-01
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
NCT06287229 2026-04-24
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03160079 2025-11-10
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
University of California, San Diego
Phase 1/2 Completed
NCT05182385 2025-07-25
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Goethe University
Phase 1/2 Active not recruiting
NCT01471782 2017-02-08
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH
Phase 1/2 Completed